PCI BIOTECH HOLDING ASA (PCIB.OL) Stock Price & Overview
OSL:PCIB • NO0010405640
Current stock price
The current stock price of PCIB.OL is 0.185 NOK. Today PCIB.OL is up by 2.21%. In the past month the price decreased by -13.4%. In the past year, price decreased by -86.43%.
PCIB.OL Key Statistics
- Market Cap
- 6.906M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.44
- Dividend Yield
- N/A
PCIB.OL Stock Performance
PCIB.OL Stock Chart
PCIB.OL Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to PCIB.OL. When comparing the yearly performance of all stocks, PCIB.OL is a bad performer in the overall market: 98.83% of all stocks are doing better.
PCIB.OL Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PCIB.OL. While PCIB.OL seems to be doing ok healthwise, there are quite some concerns on its profitability.
PCIB.OL Earnings
PCIB.OL Forecast & Estimates
PCIB.OL Groups
Sector & Classification
PCIB.OL Financial Highlights
Over the last trailing twelve months PCIB.OL reported a non-GAAP Earnings per Share(EPS) of -0.44. The EPS increased by 19.2% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -88.63% | ||
| ROE | -131.18% | ||
| Debt/Equity | 0 |
PCIB.OL Ownership
PCIB.OL Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1AE | ARGENX SE | 25.47 | 38.133B | ||
| ARGX | ARGENX SE | 24.79 | 38.12B | ||
| 22UA | BIONTECH SE-ADR | N/A | 19.212B | ||
| ABVX | ABIVAX SA | N/A | 8.666B | ||
| 2X1 | ABIVAX SA | N/A | 8.635B | ||
| GLPG | GALAPAGOS NV | N/A | 1.904B | ||
| GXE | GALAPAGOS NV | N/A | 1.877B | ||
| NANO | NANOBIOTIX | N/A | 1.362B | ||
| IVA | INVENTIVA SA | N/A | 1.09B | ||
| 6IV | INVENTIVA SA | N/A | 1.087B | ||
| PHIL | PHILOGEN SPA | 18.49 | 666.672M | ||
| XUP | GENFIT | 917.65 | 468.027M | ||
| GNFT | GENFIT | 862.25 | 438.775M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Oslo Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About PCIB.OL
Company Profile
PCI Biotech Holding ASA engages in the research and development of biopharmaceutical products for cancer treatment. The company is headquartered in Oslo, Oslo and currently employs 7 full-time employees. The company went IPO on 2008-06-18. The firm is developing therapeutic products based on its photochemical internalisation (PCI) technology. PCI Biotech’s product is the photosensitiser fimaporfin (Amphinex). The PCI technology can enhance the effect of anticancer drugs by targeted, light-directed drug delivery into cancer cells, and can also be used as a platform that may both potentiate the effect of vaccines and enable macromolecules to reach intracellular targets. The PCI technology platform consists of two elements: a small molecule photosensitiser (named fimaporfin) and a light source. The primary aim of PCI is to introduce drug molecules or macromolecules into the cytosol of the target cells. The company is this drug or macromolecule that gives the biological effect in a PCI treatment, and the intended biological effect may range from cell killing, through modification of gene expression to enhanced antigen presentation.
Company Info
IPO: 2008-06-18
PCI BIOTECH HOLDING ASA
Ullernchauseen 64
Oslo OSLO NO
Employees: 5
Phone: 4767115400
PCI BIOTECH HOLDING ASA / PCIB.OL FAQ
What does PCIB do?
PCI Biotech Holding ASA engages in the research and development of biopharmaceutical products for cancer treatment. The company is headquartered in Oslo, Oslo and currently employs 7 full-time employees. The company went IPO on 2008-06-18. The firm is developing therapeutic products based on its photochemical internalisation (PCI) technology. PCI Biotech’s product is the photosensitiser fimaporfin (Amphinex). The PCI technology can enhance the effect of anticancer drugs by targeted, light-directed drug delivery into cancer cells, and can also be used as a platform that may both potentiate the effect of vaccines and enable macromolecules to reach intracellular targets. The PCI technology platform consists of two elements: a small molecule photosensitiser (named fimaporfin) and a light source. The primary aim of PCI is to introduce drug molecules or macromolecules into the cytosol of the target cells. The company is this drug or macromolecule that gives the biological effect in a PCI treatment, and the intended biological effect may range from cell killing, through modification of gene expression to enhanced antigen presentation.
What is the stock price of PCI BIOTECH HOLDING ASA today?
The current stock price of PCIB.OL is 0.185 NOK. The price increased by 2.21% in the last trading session.
Does PCIB stock pay dividends?
PCIB.OL does not pay a dividend.
What is the ChartMill rating of PCI BIOTECH HOLDING ASA stock?
PCIB.OL has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists PCIB stock?
PCIB.OL stock is listed on the Euronext Oslo exchange.
What is the GICS sector and industry of PCIB stock?
PCI BIOTECH HOLDING ASA (PCIB.OL) operates in the Health Care sector and the Biotechnology industry.
Can you provide the market cap for PCI BIOTECH HOLDING ASA?
PCI BIOTECH HOLDING ASA (PCIB.OL) has a market capitalization of 6.91M NOK. This makes PCIB.OL a Nano Cap stock.